Previous 10 | Next 10 |
2023-10-02 10:04:07 ET DENVER, Colo., Oct 2, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Icecure Medical Ltd (NASDAQ: ICCM), Femasys (NASDAQ: FEMY), AERWINS Technologies (NASDAQ: AWIN), Invitae (NYSE:...
2023-10-02 09:19:31 ET More on IceCure Medical IceCure Medical Ltd (ICCM) Q2 2023 Earnings Call Transcript IceCure Medical shares plunge 40% on FDA update IceCure Medical's ProSense System for tumor treatment receives regulatory nod in Brazil Seeking Alpha...
2023-10-02 08:31:38 ET (24/7 MARKET NEWS) – IceCure Medical Ltd. (NASDAQ: ICCM) stated, this morning, that new data, from a study that was conducted in Spain with women who declined standard of care surgery, was presented at the European Society of Breast Imaging (“EUSOBI ...
Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Succes...
Renowned Spanish Radiologist Lucía Graña-López to Present Data Using IceCure Medical's ProSense at European Society of Breast Imaging Scientific Meeting 2023 PR Newswire Growing body of evidence-based data is giving women a minimally invasive alternative to ...
2023-09-20 12:10:04 ET More on IceCure Medical Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for IceCure Medical Financial information for IceCure Medical IceCure Medical Ltd (ICCM) Q2 2023 Earnings Call Transcript Ic...
IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer PR Newswire CAESAREA, Israel , Sept. 20, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablat...
IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress PR Newswire ProSense is gaining commercial traction in Europe where it has CE approval for numerous malignant and benign tis...
2023-09-05 09:40:06 ET More on IceCure Medical Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for IceCure Medical Financial information for IceCure Medical IceCure Medical Ltd ( ICCM ) Q2 2023 Earnings Call Transcript ...
IceCure Medical's ProSense Cryoablation System Receives Regulatory Approval in Brazil PR Newswire $6.6 million in sales expected in Brazilian market over the next five years per distribution agreement guarantees High level of early interest in ProSense...
News, Short Squeeze, Breakout and More Instantly...
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society PR Newswire Demand for minimally invasive breast cancer treatment was ove...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment fo...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medic...